

MINISTRY OF PUBLIC HEALTH OF UKRAINE
NATIONAL UNIVERSITY OF PHARMACY

**TOPICAL ISSUES
OF NEW DRUGS DEVELOPMENT**

Vol. 2

April 20, 2017
Kharkiv

Kharkiv
NUPh
2017

VACCINOPROPHYLAXIS OF POLYOMYELITIS IN UKRAINE

Gubenko E. S.

Scientific supervisor: PhD, associate prof. Kashuta V. E.

National university of Pharmacy, Kharkiv, Ukraine

eakaterinags@mail.ru

Introduction. Poliomyelitis is a highly infectious viral disease transmitted from person to person by the fecal-oral route, and is characterized by the defeat of the nervous system, predominantly the gray matter of the spinal cord, with the development of flaccid paresis and paralysis. There are no specific medicine for the treatment of poliomyelitis. In the 50 years of the last century, 2 vaccines were received: the inactivated (inanimate) Salk vaccine (IPV) and the live Sabin vaccine (OPV) (both preparations contain all 3 types of poliovirus). After this was beginning of mass vaccination against poliomyelitis and the incidence of this infection began to decline dramatically. In 2014, only 359 cases were registered in two countries (Afghanistan and Pakistan). The main disadvantage of OPV is the probability of development in vaccine and contact with them vaccine-associated paralytic poliomyelitis (VAPP). The frequency of VAPP development ranges from 500,000 to 1,000,000 first doses of OPV per case of paralytic poliomyelitis. The most frequently called VAPP is type 2 poliovirus. WHO recommends the use of a bivalent OPV vaccine that does not contain a strain of type 2 poliovirus. Ukraine joined the WHO Global Strategy – the transition from trivalent OPV to bivalent OPV.

Aim. To study the features of vaccine prevention of poliomyelitis in connection with the emergence of an outbreak in Ukraine.

Materials and methods. We have studied the WHO resolution on poliomyelitis eradication in the world, the strategic polio eradication plan and the implementation of the final phase in 2013-2018.

Results and discussion. For today in Ukraine there is an active immunization of children. In connection with the emerged deficit polio vaccine for 2015, as humanitarian aid to Canada with the support of UNICEF, Ukraine was delivered 3700000 doses OPV and 1100000 doses IPV produced by the French company Sanofi Pasteur. IPV (IMOVAKS POLIO) and OPV (OPVERO) vaccines are distributed in the regions of Ukraine. During the immunization period, out of the planned 3798258 children from 2 months to 10 years of age, received at least 1 dose of OPV, which is 90,1%. The UN Children's Fund "UNICEF" conducted a series of trainings to raise awareness of physicians in each area.

Conclusions. Due to additional immunization against poliomyelitis, it was possible to increase the level of protection of children from the disease and thus the circulation of the virus was suspended.

13. MODERN PHARMACOTHERAPY	149
Aravina V. V.; Sc. s.: Kireev I. V.	150
Bunyatyan N. D., Oborotova N. A., Nikolaeva L. L.	151
Butenko O. F.; Sc. s.: Ryabova O. O.	152
Dercach A. O.; Sc. s.: Tryshchuk N. M.	153
Gubenko E. S.; Sc. s.: Kashuta V. E.	154
Kovalenko I. S., Semchenko A. S.; Sc. s.: Zhabotynska N. V.	155
Krivykh M. A., Kornilova O. G., Bunyatyan N. D., Mosyagin V. D., Bondarev V. P., Olefir J. V.	156
Lavrova A. D.; Sc. s.: Ryabova O. O.	157
Lukianchuk J. O.; Sc. s.: Drogovoz S. M.	158
Lytvynenko Y. Y.; Sc. s.: Kashuta V. E.	159
Mirenkova P. V.; Sc. s.: Savokhina M. V.	160
Morgunov A. V.; Sc. s.: Tryshchuk N. M.	161
Prystenska A. V.; Sc. s.: Ryabova O. O.	162
Putnenko N. A.; Sc. s.: Zhabotynska N. V.	163
Rakeev P.; Sc. s.: Drogovoz S. M.	164
Tolmacheva K. S.; Sc. s.: Kireev I. V.	165
Vodolazskaya Y. A.; Sc. s.: Tryshchuk N. M.	166
Žmudzka E., Lustyk K., Jakubczyk M., Jaškowska J., Kołaczkowski M.; Sc. s.: Sapa J., Pytka K.	167
	168
14. PHARMACOECONOMIC STUDIES OF DRUGS	170
Ashfennar Sarah; Sc. s.: Gerasymova O. A.	171
Berdnik O.G.; Sc. s.: Tsubanova N. A.	172
Gorbachenko C.; Sc. s.: Matyashova N.A.	173
Jaloliddinova M. Sh, Zufarova Z. Kh.; Sc. s.: Yunusova Kh. M.	174
Lotfi El Mehdi; Sc. s.: Tkachova O. V., Sakharova T. S.	176
Podgainaya V. L.; Sc. s.: Bezditko N. V.	177
Sharifov Ch. Sh.; Sc. s.: Zaychenko G. V., Mishchenko O. Ya., Khalieieva O. L.	178
Voznyak I. V., Bondarenko O. I.; Sc. s.: Mishchenko O. Ya., Ostashko V. F.	179
15. MANAGEMENT AND MARKETING IN PHARMACY	180
Al Batat Alaa Kadhim Ali; Sc. s.: Sofronova I. V.	181
Aliyeva L. S., Kobets M. N., Kobets Yu. N.	182
Al-Obaidi Mustafa Sameer Abdolwahhab; Sc. s.: Sofronova I. V.	183
Mala Zh. V.; Sc. s.: Posylkina O. V.	184
Postoy V. V.; Sc. s.: Vyshnevska L. I.	185
Pyrlyk D. O.; Sc. s.: Bondarieva I. V.	186
Rouached R.; Sc. s.: Zhadko S. V.	187